Business
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
NEW YORK, July 11, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for
About this update from Nexttrip, Inc.
[{"type":"text","content":" NEW YORK, July 11, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease (\"AD\") is announcing that Dr. Daniel L. Alkon, the Company's President and CSO, will be honored among the recipients of the Cure Coin Award, at the InvestAcure Cure Coin Awards Reception on July 15, 2019 during the Alzheimer's Association International Conference in Los Angeles. \n\"We are proud to honor Dr. Alkon for his work in the development of Bryostatin, a natural compound showing promise in restoring synaptic networks in the brain, preventing neuronal death, clearing Tau and Amyloid buildup, and reversing Alzheimer's memory loss even for patients with late-stage disease,\" said Max Tokarsky, Founder & CEO of InvestAcure, PBC. \nThe award reception will bring together key stakeholders in the battle against AD, Dementia and CTE to honor industry scientists working to develop groundbreaking discoveries into effective treatments. NFL 'super-agent' Leigh Steinberg and former Vice Chairman of the NASDAQ David Weild IV are scheduled to host and keynote the event. The event program will also feature a presentation by InvestAcure, PBC Founder and CEO, Max Tokarsky, on their plans to drive $1 billion in annual investment for AD R&D until a cure is found. \nThe reception will be held at 7:00 p.m. at The Association on 110 E 6th Street in Downtown Los Angeles. InvestAcure welcomes members of the press to request attendance at the event. The event is expected to be at capacity, so please register as soon as possible. For additional details and registration, please visit the event page. \nNeurotrope's Chief Executive Officer, Dr. Charles S. Ryan, will present the design of its confirmatory Phase 2 double blind, placebo controlled clinical trial of bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia. The study design will be presented as a poster and Dr. Ryan will deliver an oral presentation. \"We are delighted that the work of Dr. Alkon will be recognized, and look forward to the opportunity to present details of our confirmatory trial that will inform the development of a pivotal trial protocol for Bryostatin-1 in moderate-to-severe AD patients,\" said Dr. Ryan.\nThe poster presentation informatio...